CORRECTING and REPLACING Berman Tabacco Investigates Omnicell, Inc.
July 11 2019 - 5:09PM
Business Wire
URL in fourth paragraph should read:
https://www.bermantabacco.com/case/omnicell-inc/
The corrected release reads:
BERMAN TABACCO INVESTIGATES OMNICELL, INC.
Berman Tabacco, (www.bermantabacco.com), a national law firm
representing investors is investigating possible securities law
violations involving Omnicell, Inc. (“Omnicell” or the “Company”)
(Nasdaq: OMCL).
Omnicell provides medication and supply dispensing automation
solutions, central pharmacy automation solutions, analytics
software, and medication adherence solutions which are sold in its
principal market, which is the healthcare industry. The Company is
based in Mountain View, California.
On July 11, 2019, Bloomberg reported in an article titled
“Omnicell Drops After Cautious Mention at Glasshouse Research” that
shares of Omnicell had fallen as much as 7.2% after GlassHouse
research “said the shares may have 59% downside due to accounting
issues at the company.” According to Bloomberg, GlassHouse alleges,
among other things, that the Company is “prematurely recognizing
revenue and failing to write-off legacy inventory.”
If you would like more information regarding this investigation,
or if you wish to share information about the investigation, you
may can find more information here:
https://www.bermantabacco.com/case/omnicell-inc/
Berman Tabacco is a national law firm representing institutions
and individuals in lawsuits, seeking to recoup losses caused by
violations of securities and antitrust laws. The firm has 37
lawyers in Boston and San Francisco.
This notice may constitute attorney advertising.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005835/en/
Chowning Poppler cpoppler@bermantabacco.com (800) 516-9926 or
(415) 433-3200